Vaxcyte, Inc. (PCVX): Shareholders' Equity
$2.69B
As of 2025-12-31
$2.76B
As of 2026-06-30
+41.2%
3-year compound annual growth
+50.7%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.69B | -18.8% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $3.31B | +166.5% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $1.24B | +30.1% | 2026-02-24, Balance as of period end |
| 2022-12-31 | $953.61M | +235.8% | 2025-02-25, Balance as of period end |
| 2021-12-31 | $284.02M | -17.9% | 2024-02-27, Balance as of period end |
| 2020-12-31 | $345.84M | n/m | 2023-02-27, Balance as of period end |
| 2019-12-31 | -$106.37M | n/m | 2022-02-28, Balance as of period end |
| 2018-12-31 | -$57.73M | n/a | 2021-03-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | 2025-12-31 | $2.69B | -18.8% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.11B | +6.8% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.16B | -3.7% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.11B | +9.9% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $48.81M | -86.6% |
| Revolution Medicines, Inc. (RVMD) | 2025-12-31 | $1.63B | -28.0% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $1.92B | -0.5% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $3.25B | +25.6% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.58B | +89.0% |
Compare PCVX, RGEN, EXEL, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗